PharVision Advisers’s CSX Corp CSX Stock Holding History

PharVision Advisers’s Portfolio CSX Stock Details CSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-7,343	Closed	-$216K	–	299
2025 Q1	$216K	Buy	+7,343	New	+$233K	0.3%	178

Other funds holding CSX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

PharVision Advisers's CSX Position: Q2 2025 in Review

PharVision Advisers sold out of CSX Corp (CSX) in Q2 2025, closing a stake of 7,343 shares — an estimated $216K sold.

PharVision Advisers first reported a position in CSX in Q1 2025 and held it in 1 quarter. The position peaked at $216K in Q1 2025. 1,697 funds tracked by Wall St. Rank hold CSX as of Q2 2025.

PharVision Advisers reported no remaining CSX Corp position as of Q2 2025 after selling out during the quarter.
PharVision Advisers sold 7,343 CSX Corp shares in Q2 2025, an estimated $216K.
PharVision Advisers first reported a position in CSX Corp in Q1 2025 and held it in 1 quarter.
PharVision Advisers's CSX Corp position peaked at $216K in Q1 2025.
1,697 funds tracked by Wall St. Rank held CSX Corp as of Q2 2025.

Based on PharVision Advisers's 13F filing for Q2 2025, filed 13 Aug 2025.